eli lilly glp-1 agonist As Use Expands, Long-Term Safety Questions Remain Under Watch Eli Lilly's Next-Generation GLP-1R Agonist

GLP-1 receptor agonists are designed to resist rapid enzymatic degradation, thereby allowing sustained receptor activation

EX, Exenatide EX-LAR, Long-acting release formulation of exenatide

Pipeline (Phase 3 trials completed, FDA decision pending as of April 2026): Survodutide (BI 456906): Dual GLP-1/glucagon agonist from Boehringer Ingelheim

Among the diverse array of antidiabetic agents, the class of GLP-1 receptor agonists has garnered substantial attention not only for their glycemic control properties but also for their potential cardiovascular benefits (35)

Since the activation of these pathways sometimes produces opposite effects, the concurrent action on two or more of them could result in a complementary and synergistic effect [154]